 |
|
|
|
December 1999 Cover
|
|
Scientists at Merck are gearing up to begin human clinical trials of two AIDS vaccines in healthy uninfected individuals by the end of the year. The tests will
be undertaken to establish whether the immune system response observed in vaccinated animals will be repeated in humans; however, data from the animal studies are
still being analyzed.
Merck declined to elaborate on the DNA AIDS vaccines, but said animal studies indicated the vaccine can induce a killer and T-cell response. The human
studies primarily will concentrate on the vaccines' ability to encourage the immune system to generate white blood cells, called killer or cytotoxic T-cells: individuals
infected with the virus who also produce significant amounts of those cells are able to keep the disease at bay.
Editor's Note: from the Wall Street Journal
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
